|产品介绍||Lorcaserin HCl是一种选择性的人源5-HT2C受体完全激动剂，Ki值为15 nM|
|别名||绿卡色林盐酸盐; (R)-8-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并氮杂卓盐酸盐;(R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride|
BELVIQ (lorcaserin hydrochloride) is a serotonin 2C receptor?agonist?for oral administration used for chronic weight management. Lorcaserin is a highly selective 5-HT2C receptor agonist developed for the treatment of obesity. In rats, lorcaserin led to dose-dependent wt. loss. Lorcaserin proved safe and well tolerated in healthy volunteers and obese patients. In a phase II clin. study, patients administered 20 mg/day lorcaserin achieved an av. wt. loss of 3.6 kg (7.9 lbs), which was significantly greater than the av. wt. loss of 0.3 kg (0.7 lbs) in the placebo group. A phase III clin. trial is ongoing to evaluate the long-term safety and efficacy of lorcaserin in patients with obesity.